Publications by authors named "Marta Bellone"

Claim this Profile
A
Acute Myeloid and Lymphoblastic Leukemia Cell Interactions with Endothelial Selectins: Critical Role of PSGL-1, CD44 and CD43.
Caroline Spertini, Bénédicte Baïsse, Marta Bellone, Milica Gikic, Tatiana Smirnova

Cancers (Basel)· August 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Eradication of chemotherapy-resistant CD44+ human ovarian cancer stem cells in mice by intraperitoneal administration of Clostridium perfringens enterotoxin.
Francesca Casagrande, Emiliano Cocco, Stefania Bellone, Christine E Richter, Marta Bellone

Cancer· December 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Tissue factor expression in ovarian cancer: implications for immunotherapy with hI-con1, a factor VII-IgGF(c) chimeric protein targeting tissue factor.
Emiliano Cocco, Joyce Varughese, Natalia Buza, Stefania Bellone, Ken-Yu Lin, Marta Bellone

Clin Exp Metastasis· October 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Expression of αV-integrins in uterine serous papillary carcinomas; implications for targeted therapy with intetumumab (CNTO 95), a fully human antagonist anti-αV-integrin antibody.
Marta Bellone, Emiliano Cocco, Joyce Varughese, Stefania Bellone, Paola Todeschini

Int J Gynecol Cancer· August 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
U
Uterine serous papillary carcinomas overexpress human trophoblast-cell-surface marker (Trop-2) and are highly sensitive to immunotherapy with hRS7, a humanized anti-Trop-2 monoclonal antibody.
Joyce Varughese, Emiliano Cocco, Stefania Bellone, Maria de Leon, Marta Bellone

Cancer· July 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
High-grade, chemotherapy-resistant primary ovarian carcinoma cell lines overexpress human trophoblast cell-surface marker (Trop-2) and are highly sensitive to immunotherapy with hRS7, a humanized monoclonal anti-Trop-2 antibody.
Joyce Varughese, Emiliano Cocco, Stefania Bellone, Marta Bellone, Paola Todeschini

Gynecol Oncol· July 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Expression of tissue factor in adenocarcinoma and squamous cell carcinoma of the uterine cervix: implications for immunotherapy with hI-con1, a factor VII-IgGFc chimeric protein targeting tissue factor.
Emiliano Cocco, Joyce Varughese, Natalia Buza, Stefania Bellone, Michelle Glasgow, Marta Bellone

BMC Cancer· June 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Primary cervical carcinoma cell lines overexpress epithelial cell adhesion molecule (EpCAM) and are highly sensitive to immunotherapy with MT201, a fully human monoclonal anti-EpCAM antibody.
Christine E Richter, Emiliano Cocco, Stefania Bellone, Marta Bellone, Francesca Casagrande

Int J Gynecol Cancer· December 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
Higher sensitivity to patupilone versus paclitaxel chemotherapy in primary uterine serous papillary carcinoma cell lines with high versus low HER-2/neu expression in vitro.
Daniel Paik, Emiliano Cocco, Stefania Bellone, Francesca Casagrande, Marta Bellone

Gynecol Oncol· October 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Clostridium perfringens enterotoxin carboxy-terminal fragment is a novel tumor-homing peptide for human ovarian cancer.
Emiliano Cocco, Francesca Casagrande, Stefania Bellone, Christine E Richter, Marta Bellone

BMC Cancer· July 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Overexpression of EpCAM in uterine serous papillary carcinoma: implications for EpCAM-specific immunotherapy with human monoclonal antibody adecatumumab (MT201).
Karim El-Sahwi, Stefania Bellone, Emiliano Cocco, Francesca Casagrande, Marta Bellone

Mol Cancer Ther· January 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis